Creso Pharma Limited (COPHF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Creso Pharma Limited (COPHF) trades at $0.12 with AI Score 56/100 (Grade B). Creso Pharma Limited develops and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products. Market cap: $131.72M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for COPHF: COPHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates COPHF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
COPHF: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Creso Pharma Limited (COPHF) Healthcare & Pipeline Overview
Creso Pharma Limited focuses on developing and commercializing cannabis and hemp-based products for both human and animal health, operating in a global market with a diverse product portfolio including nutraceuticals and therapeutic treatments, but faces challenges related to profitability and market competition.
What Is the Investment Thesis for COPHF?
Creso Pharma Limited presents a speculative investment opportunity within the rapidly evolving cannabis and hemp-based health and wellness market. The company's diverse product portfolio targeting both human and animal health provides multiple revenue streams. However, the company's negative profit margin of -377.3% raises concerns about its financial sustainability. Investors should closely monitor Creso Pharma's ability to improve its profitability and achieve sustainable growth. Key catalysts include successful product launches and expansion into new geographic markets. The high beta of -24.81 indicates extreme volatility compared to the market, suggesting a high-risk investment profile. The company's ability to navigate regulatory hurdles and maintain a competitive edge will be crucial for its long-term success.
Based on FMP financials and quantitative analysis
COPHF Key Highlights
- Market capitalization of $131.72M indicates a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -0.40 reflects the company's current lack of profitability.
- Profit margin of -377.3% highlights significant challenges in achieving profitability.
- Gross margin of 3.3% suggests limited ability to generate profit from sales after accounting for the cost of goods sold.
- Beta of -24.81 indicates extreme volatility compared to the market.
Who Are COPHF's Competitors?
COPHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AAPGV Ascentage Pharma Group International | $17.38 | +0.75% | $127.31M | 46 |
| AMEUF Anteris Technologies Ltd | $5.70 | -35.81% | $120.50M | 57 |
| AMGXF AnGes, Inc. | $0.36 | +0.00% | $142.50M | 59 |
| CMXC Cell MedX Corp. | $0.42 | +0.00% | $126.33M | 44 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are COPHF's Key Strengths?
- Diverse product portfolio targeting both human and animal health.
- Presence in multiple geographic regions.
- Focus on pharmaceutical-grade cannabis and hemp-based products.
- Established cultivation and processing capabilities.
What Are COPHF's Weaknesses?
- Negative profit margin and limited profitability.
- High beta indicating significant market volatility.
- Reliance on evolving regulatory landscape.
- Limited brand recognition compared to larger competitors.
What Could Drive COPHF Stock Higher?
- Potential regulatory approvals for new cannabis and hemp-based products in key markets.
- Expansion of distribution network through strategic partnerships.
- Increasing consumer acceptance of cannabis and hemp-based health and wellness products.
- Launch of new innovative products targeting specific therapeutic areas.
- Growing demand for animal health products containing cannabis and hemp.
What Are the Key Risks for COPHF?
- Financial-distress signal — its Altman Z-Score of -15.08 sits in the distress zone (elevated bankruptcy risk).
- Changes in regulatory landscape and stricter regulations on cannabis and hemp products.
- Intense competition from established pharmaceutical companies and other cannabis producers.
- Fluctuations in cannabis and hemp prices affecting profitability.
- Negative public perception of cannabis products impacting demand.
- Limited financial resources and potential need for additional funding.
What Are the Growth Opportunities for COPHF?
- Expansion into New Geographic Markets: Creso Pharma can drive growth by expanding its presence in key markets such as North America and Europe. The increasing legalization of cannabis and hemp-based products in these regions presents significant opportunities for market penetration. Strategic partnerships with local distributors and retailers can facilitate market entry and accelerate revenue growth. The global cannabis market is projected to reach $47 billion by 2027, providing a substantial addressable market for Creso Pharma.
- Development of Innovative Products: Investing in research and development to create innovative cannabis and hemp-based products can drive growth and differentiate Creso Pharma from its competitors. Focusing on specific therapeutic areas, such as pain management and mental health, can attract a loyal customer base and generate recurring revenue. The nutraceutical market is expected to grow to $400 billion by 2030, offering a significant opportunity for Creso Pharma to expand its product portfolio.
- Strategic Acquisitions and Partnerships: Pursuing strategic acquisitions and partnerships with other companies in the cannabis and hemp industry can accelerate growth and expand Creso Pharma's market reach. Acquiring companies with complementary product portfolios or established distribution networks can create synergies and enhance the company's competitive position. The cannabis industry is consolidating, with larger companies acquiring smaller players to gain market share and expand their operations.
- Focus on Animal Health Products: The animal health market presents a significant growth opportunity for Creso Pharma, particularly with its anibidiol product. As pet owners increasingly seek natural and alternative treatments for their animals, the demand for cannabis and hemp-based products for pets is expected to grow. Expanding the anibidiol product line and developing new animal health products can drive revenue growth and establish Creso Pharma as a leader in this niche market. The global animal health market is projected to reach $70 billion by 2027.
- Enhancing E-commerce Capabilities: Investing in e-commerce capabilities and online marketing can drive direct-to-consumer sales and expand Creso Pharma's customer base. Developing a user-friendly online platform and implementing targeted marketing campaigns can attract new customers and increase brand awareness. The e-commerce market is growing rapidly, with consumers increasingly purchasing health and wellness products online. Strengthening its online presence can enable Creso Pharma to reach a wider audience and generate higher sales.
What Opportunities Does COPHF Have?
- Expansion into new geographic markets.
- Development of innovative cannabis and hemp-based products.
- Strategic acquisitions and partnerships.
- Growth in the animal health market.
What Threats Does COPHF Face?
- Intense competition from established pharmaceutical companies and other cannabis producers.
- Changing regulatory landscape and potential for stricter regulations.
- Fluctuations in cannabis and hemp prices.
- Potential for negative public perception of cannabis products.
What Are COPHF's Competitive Advantages?
- Proprietary formulations and intellectual property related to cannabis and hemp-based products.
- Established presence in multiple geographic regions, including Europe, the Middle East, North America, and Asia Pacific.
- Focus on pharmaceutical-grade products, ensuring high quality and safety standards.
- Diverse product portfolio targeting both human and animal health.
What Does COPHF Do?
Creso Pharma Limited, established in 2015 and headquartered in Nedlands, Australia, is a healthcare company specializing in the development, registration, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products. The company's mission is to provide innovative and effective treatments for both human and animal health. Creso Pharma operates across several key regions, including Europe, the Middle East, North America, and the Asia Pacific, reflecting its global ambitions and market reach. The company's product portfolio includes a range of therapeutic and nutraceutical products. Key offerings include anibidiol, a complementary feed product designed for companion animals to support their well-being. CannaQIX is another prominent product, a nutraceutical containing hemp oil extract, vitamins, and zinc, aimed at reducing stress and supporting psychological and nervous functions. Additionally, Creso Pharma develops and markets topical and skin care products, such as cannaDOL, a CBD-based topical gel formulated with cooling and warming essential oils. Creso Pharma's business activities encompass the entire value chain, from cultivation and processing of cannabis to the manufacturing and distribution of finished products. The company cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products, ensuring a consistent supply and quality control. Creso Pharma aims to establish itself as a leader in the cannabis and hemp-based health and wellness sector through continuous innovation, strategic partnerships, and expansion into new markets.
What Products and Services Does COPHF Offer?
- Develops pharmaceutical-grade cannabis products.
- Registers and commercializes cannabis and hemp-based nutraceuticals.
- Creates treatments for human health using cannabis and hemp.
- Develops treatments for animal health using cannabis and hemp.
- Cultivates and processes cannabis products.
- Supplies cannabis retail products.
- Markets topical and skin care products containing CBD.
How Does COPHF Make Money?
- Develops and sells cannabis and hemp-based products for human and animal health.
- Generates revenue through the sale of nutraceuticals and therapeutic products.
- Cultivates and processes cannabis to ensure product quality and supply.
- Distributes products through retail channels and online platforms.
What Industry Does COPHF Operate In?
Creso Pharma Limited operates within the rapidly expanding cannabis and hemp-based health and wellness industry. This sector is characterized by increasing consumer acceptance, evolving regulatory landscapes, and growing demand for alternative health solutions. The market is highly competitive, with numerous companies vying for market share. Creso Pharma's focus on pharmaceutical-grade products and its presence in multiple geographic regions position it to capitalize on the industry's growth. However, the company faces competition from established pharmaceutical companies and other cannabis producers. The global cannabis market is projected to reach billions of dollars in the coming years, presenting significant opportunities for companies like Creso Pharma.
Who Are COPHF's Key Customers?
- Individuals seeking alternative health and wellness solutions.
- Pet owners looking for natural treatments for their animals.
- Retailers and distributors of health and wellness products.
- Pharmacies and healthcare providers.
Company Profile
Creso Pharma Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Nedlands, AU. The company is led by CEO William Lay. COPHF has traded publicly since 2017.
F-Score 4/9Financial Health
Creso Pharma Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -15.08 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -86.3%, showing how much profit it generates from its asset base. A current ratio of 0.76 means current liabilities exceed short-term assets, a liquidity point worth watching.
COPHF Valuation & Market Position
With a $131.72M market cap, Creso Pharma Limited sits in the micro-cap segment of the market. Relative to its peer group, COPHF's quantitative score of 56/100 is roughly in line with the peer average of 54/100.
COPHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diverse product portfolio targeting both human and animal health.
- Presence in multiple geographic regions.
- Focus on pharmaceutical-grade cannabis and hemp-based products.
- Established cultivation and processing capabilities.
Bear Case
- Negative profit margin and limited profitability.
- High beta indicating significant market volatility.
- Reliance on evolving regulatory landscape.
- Limited brand recognition compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
COPHF Latest News
No recent news available for COPHF.
COPHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for COPHF.
Price Targets
Wall Street price target analysis for COPHF.
COPHF MoonshotScore
What does this score mean?
The MoonshotScore rates COPHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: William Lay
CEO
William Lay serves as the CEO of Creso Pharma Limited. His background includes extensive experience in the pharmaceutical and healthcare industries, with a focus on strategic leadership and business development. He has held various leadership positions in both public and private companies, contributing to his expertise in navigating complex regulatory environments and driving growth. His experience encompasses product development, commercialization, and market expansion strategies.
Track Record: Under William Lay's leadership, Creso Pharma has focused on expanding its product portfolio and geographic reach. Key achievements include the launch of new cannabis and hemp-based products and the establishment of strategic partnerships to enhance distribution capabilities. He has also overseen efforts to improve operational efficiency and strengthen the company's financial position. His strategic decisions have been instrumental in positioning Creso Pharma for long-term growth in the evolving cannabis market.
COPHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Creso Pharma Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and greater price volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher price volatility compared to stocks listed on major exchanges.
- Risk of delisting or suspension from the OTC market.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor the company's news and press releases for any material developments.
- Consult with a financial advisor before making any investment decisions.
- Check for any history of regulatory actions or legal disputes.
- Company has been in operation since 2015.
- Presence in multiple geographic regions.
- Focus on pharmaceutical-grade products.
- Development of products for both human and animal health.
Common Questions About COPHF (Healthcare)
What does Creso Pharma Limited do?
Creso Pharma Limited is a healthcare company that develops, registers, and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. They operate in Europe, the Middle East, North America, and the Asia Pacific. Their product range includes anibidiol for animals, cannaQIX for stress reduction in humans, and cannaDOL for topical skin care, positioning them as a diversified player in the cannabis-based health and wellness market.
What do analysts say about COPHF stock?
Analyst sentiment on COPHF is currently not available due to limited coverage. Key valuation metrics such as P/E ratio (-0.40) and profit margin (-377.3%) indicate financial challenges. Growth considerations revolve around successful product launches, market expansion, and regulatory approvals. Investors should conduct thorough due diligence and assess the company's ability to improve profitability and achieve sustainable growth before making any investment decisions.
What are the main risks for COPHF?
Creso Pharma Limited faces several risks, including intense competition in the cannabis and hemp-based health and wellness market. The evolving regulatory landscape presents uncertainty, with potential for stricter regulations impacting the company's operations. Financial risks include negative profit margins and the need for additional funding. Fluctuations in cannabis and hemp prices can also affect profitability. Investors should carefully consider these risks before investing in COPHF.
What are the key factors to evaluate for COPHF?
Creso Pharma Limited (COPHF) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does COPHF data refresh on this page?
COPHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven COPHF's recent stock price performance?
Creso Pharma Limited (COPHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio targeting both human and animal health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider COPHF overvalued or undervalued right now?
Valuing Creso Pharma Limited (COPHF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying COPHF?
Before investing in Creso Pharma Limited (COPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited and less reliable than data for exchange-listed companies.
- Analyst sentiment is based on limited coverage and may not be representative of the broader market.